All products / DC11448
CAT. NO. DC11448
LOXO 195(Selitrectinib)
Pack sizes and prices
| Pack size | Price |
|---|---|
| 100 mg | $750 USDRequest a quote → |
| 250 mg | $1,400 USDRequest a quote → |
| 1 g | $2,800 USDRequest a quote → |
In stock. Contact our team for lead time, shipping and final quotation.
Product overview
LOXO-195 is a next-generation TRK kinase inhibitor (TKI), with IC50s of 0.6 nM, <2.5 nM for TRKA and TRKC respectively.
For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.
Identity and specifications
| Catalog number | DC11448 |
|---|---|
| Product name | LOXO 195(Selitrectinib) |
| CAS | 2097002-61-2 |
| Molecular formula | C20H21FN6O |
| Molecular weight | 380.4187 |
| Purity | >98% |
| SMILES | FC1C([H])=NC2C([H])([H])C([H])([H])[C@@]([H])(C([H])([H])[H])N([H])C(C3C([H])=NN4C([H])=C([H])C(=NC4=3)N3C([H])([H])C([H])([H])C([H])([H])[C@]3([H])C=2C=1[H])=O |
Source-listed specifications; the batch COA applies.
Source and product documents
The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.
DC Chemicals — LOXO 195(Selitrectinib) (DC11448)Source references
[1]. Drilon A, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov. 2017 Sep;7(9):963-972.
